Halozyme Therapeutics: Steady Growth In A Challenged Market
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
Investor's Business Daily on MSN2d
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue
Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in ...
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?
Here is how Brookdale Senior Living (BKD) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Here’s Why Artisan Small Cap Fund Trimmed SharkNinja (SN)
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter ...
Will Novanta (NOVT) Benefit from Several Secular Growth Trends?
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter ...
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter ...
Halozyme Therapeutics’ (HALO) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO – Free Report) in a report published on Thursday,Benzinga reports. Several other equities analysts have also ...